Log in to search using one of your social media accounts:


Hepatocellular carcinoma: Resection vs. transplantation

(Deutsches Aerzteblatt International) Liver transplantation is the gold standard for treating early hepatocellular cancers. Because of the lack of donors, this option is, however, available to a limited degree only. Curative liver resection is an alternative in this setting. Markus B. Schoenberg, Julian N. Bucher, and coauthors investigated whether liver resection can yield results that are comparable to those of liver transplantation.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

We have read with interest the review by Galle et al concerning the therapeutic strategy in intermediate stage hepatocellular carcinoma (HCC)[1]. The heterogeneity of this group is highlighted, whereas only transarterial chemoembolization (TACE) is recommended in the guidelines. However, some (Barcelona Clinic Liver Cancer) BCLC B patients may not benefit from TACE. Thus, in this review other therapeutic approaches are discussed, based on a very exhaustive review of the literature, from transplantation to the most recent systemic treatments such as immunotherapy.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
Conclusion: The incorporation of 11C-choline PET/CT into the MDT discussion altered the diagnosis/treatment of one-third of HCC patients. We propose a novel diagnostic algorithm to be refined in referral centers for HCC management.
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Original Articles Source Type: research
Authors: Usmani A, Mishra A, Ahmad M Abstract The liver is an imperative organ of tremendous importance concerned with maintenance of metabolic functions and detoxification of exogenous and endogenous challenges like xenobiotics, viral infections and chronic alcoholism. Liver diseases particularly hepatitis B virus infections, liver cirrhosis and hepatocellular carcinoma continue to pose a significant health challenge worldwide due to the lack of therapeutic management options besides liver resection and transplantation. Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of c...
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
Abstract Actinic keratoses (AKs) are highly dynamic lesions and AK activity has been shown to be associated with squamous cell carcinoma (SCC). We sought to explore risk factors which may affect the 12-month turnover of AKs in organ transplant recipients (OTRs). The number of incident AKs, regressed AKs and net change in AK counts were calculated. Negative binomial regression and Poisson regression models were used to estimate rate ratios (RR) for these 3 outcomes. Among 150 renal and 89 liver OTRs, those who spent> 50% of a typical weekday in the sun had a lower rate of AK regression than those who spen...
Source: Acta Dermato-Venereologica - Category: Dermatology Authors: Tags: Acta Derm Venereol Source Type: research
Conclusion: In patients with nvHCC, serum ferritin levels are higher in non-diabetics and alcoholics.Liver Cancer 2017;6:307-312
Source: Liver Cancer - Category: Cancer & Oncology Source Type: research
In conclusion, CAVD is highly prevalent. Long understood as a passive process, it is now known to be complex and one which involves pathophysiological mechanisms similar to those of atherosclerosis. Understanding these mechanisms could help to establish new therapeutic targets that might allow us to halt or at least slow down the progression of the disease. Early Steps in the Tissue Engineering of Intervertebral Discs https://www.fightaging.org/archives/2017/08/early-steps-in-the-tissue-engineering-of-intervertebral-discs/ In this paper, researchers report on progress towards the manufacture of interver...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Each year, the SENS Research Foundation accepts a group of young life science academics and puts them to work on projects in aging research, both at the foundation and in allied laboratories, creating ties between research groups that can help to advance the state of the art. This year's batch has worked on a diverse set of projects that spread out beyond core SENS initiatives such as allotopic expression of mitochondrial genes. Reading through their projects is a reminder that a great deal can be accomplished these days given a small team, a little funding, and an equipped laboratory. Progress in medical research is no lo...
Source: Fight Aging! - Category: Research Authors: Tags: Healthy Life Extension Community Source Type: blogs
CONCLUSIONS: Treating HCC recurrence is a multidisciplinary workup involving hepatologists, surgeons, oncologists and radiologists in order to offer a patient-tailored therapy. PMID: 28829499 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Publication date: September–October 2017 Source:Revista Española de Medicina Nuclear e Imagen Molecular (English Edition), Volume 36, Issue 5 Author(s): L. Reguera-Berenguer, J. Orcajo-Rincón, A. Rotger-Regí, A.M. Matilla-Peña, M. Echenagusia-Boyra, R. Pérez-Pascual, A. Marí-Hualde, J.C. Alonso-Farto Hepatic radioembolization with 90Y is an increasingly widely used locoregional therapy in the treatment of hepatocellular carcinoma. Its potential benefit has recently been described as a downstaging treatment, achieving a decreased tumour burden and allowing patients to be resc...
Source: Revista Espanola de Medicina Nuclear e Imagen Molecular - Category: Nuclear Medicine Source Type: research
Hepatocellular carcinoma (HCC) is the 6th most common malignancy worldwide and is the third most common cause of cancer-related mortality [1] with a rising incidence in the United States [2]. Radical treatment options such as liver transplantation and surgical resection are available only in small number of cases with HCC. Liver transplantation is usually performed in patients with cirrhosis and HCC within the Milan criteria [3]. The limited availability of donor organs prolongs the waiting time and thus increases the chance of dropout due to tumor progression [4].
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Transplant | Transplants | Urology & Nephrology